Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2025)

Aligos Therapeutics' EBITDA Margin history spans 5 years, with the latest figure at 11756.21% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 926300.0% year-over-year to 11756.21%; the TTM value through Dec 2025 reached 1105.95%, up 97661.0%, while the annual FY2025 figure was 1105.95%, 253030.0% up from the prior year.
  • EBITDA Margin reached 11756.21% in Q4 2025 per ALGS's latest filing, down from 4251.28% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13853.38% in Q1 2025 to a low of 16326.43% in Q1 2023.
  • Average EBITDA Margin over 5 years is 2785.44%, with a median of 1789.08% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -1493152bps in 2023, then surged 1888681bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 10085.01% in 2021, then surged by 98bps to 155.63% in 2022, then tumbled by -791bps to 1385.96% in 2023, then tumbled by -80bps to 2493.21% in 2024, then crashed by -372bps to 11756.21% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's EBITDA Margin are 11756.21% (Q4 2025), 4251.28% (Q3 2025), and 1646.63% (Q2 2025).